期刊文献+

The Role of Homocysteine and Other Clinical Laboratory Markers in Assessing Cardiovascular Risk in Patients on Hemodialysis

The Role of Homocysteine and Other Clinical Laboratory Markers in Assessing Cardiovascular Risk in Patients on Hemodialysis
下载PDF
导出
摘要 Cardiovascular diseases constitute approximately 50% of deaths among dialysis patients in the USA and Europe. The increase in traditional and nontraditional cardiovascular risk factors in determining the high mortality of patients with end-stage renal disease (ESRD) is complicated due to the high frequency of risk factors in these patients. Some laboratory markers like homocysteine, albumin, cholesterol, triglycerides, LDL-cholesterol, and creatinine could be efficient in marking the risk of cardiovascular disease in these patients. We use Roche assay tests, based on routinely principles to determine this laboratory parameters used in the clinical laboratory. All laboratory parameters we measured on a biochemistry auto analyser Cobas Integra 400 at the clinical laboratory of University Hospital--Pleven. Using a statistical program a research was done on the quantitative characteristics and prognostic capabilities of homocysteine and other biochemical parameters. We determined the diagnostic specificity and sensitivity of our lab performance against vascular disease (heart attack or stroke) by ROC curves. For each of the observed values of biochemical parameters we calculated the diagnostic sensitivity and specificity. The threshold values for which the parameters have the highest sensitivity and specificity have been concluded. Summary of diagnostic value of parameters to judge the coefficient AUC--area under the curve, for cholesterol, LDL, triglycerides, albumin, it was a significant (P 〈 0.05). Homocysteine and the rest of the studied by us laboratory parameters can be regarded as laboratory markers of choice for assessing the risk of heart attack or stroke in patients on dialysis.
机构地区 UMHA T
出处 《Journal of Life Sciences》 2016年第1期48-53,共6页 生命科学(英文版)
关键词 HOMOCYSTEINE ALBUMIN end-stage renal disease cardiovascular risk factors. 同型半胱氨酸 临床实验室 心血管疾病 风险评估 血液透析 低密度脂蛋白胆固醇 患者 危险因素
  • 相关文献

参考文献18

  • 1Raine, A. E., Margreiter, R., and Brunner, F. P., et al.1992. “Report on Management of Renal Failure in Europe XXII.” 1991 Nephrol. Dial. Transplant. 1 (2): 7-35.
  • 2Levey, A. S. 1998. “Controlling the Epidemic of Cardiovascular Disease in Chronic Renal Disease: Where do We Start?” Am. J. Kidney Dis. 32 (3): 5-13.
  • 3Wilcken, D. E., and Gupta, V. J. 1979. “Sulphr Containing Amino Acids in Chronic Renal Failure with Particular Reference to Homocystine and Cysteine-homocysteine Mixed Disulphide.” Eur. J. Clin. Invest 9: 301-7.
  • 4Chauveau, P., Chadefaux, B., and Coude, M., et al. 1993. “Hyperhomocysteinemia, a Risk Factor for Atherosclerosis in Chronic Uremic Patients.” Kidney Int. 43 (41): 72-7.
  • 5Bachmann, J., Tepel, M., and Raidt, H., et al. 1995. “Hyperhomocysteinemia and the Risk for Vascular Disease in Hemodialysis Patients.” J. Am. Soc. Nephrol.: 121-5.
  • 6Bostom, A. G., Shemin, D., and Lapane, K. L., et al. 1995. “Hyperhomocysteinemia and Traditional Cardiovascular Disease Risk Factors in End-stage Renal Disease Patients on Dialysis: A Case-control Study.” Atherosclerosis 114: 93-1037. Hultberg, B., Andersson, A., and Sterner, G.1993. “Plasma Homocysteine in Renal Failure.” Clin. Nephrol. 41: 230-4.
  • 7Robinson, K., Gupta, A., and Dennis, V., et al. 1996. “Hyperhomocysteinemia Confers an Independent Increased Risk of Atherosclerosis in End-stage Renal Disease and is Closely Linked to Plasma Folate and Pyridoxine Concentrations.” Circulation 94: 2743-8.
  • 8Bostom, A., Brosnan, J. T., and Hall, B., et al. 1995. “Net Uptake of Plasma Homocysteine by the Rat Kidney in vivo.” Atherosclerosis 116: 59-62.
  • 9Guttormsen, A. B., Svarstad, E., Ueland, P. M., and Refsum, H. 1995. “Elimination of Homocysteine from Plasma in Subjects with End Stage Renal Failure.” Ir. J. Med. Sci. 164 (15): 8-9.
  • 10Sirrs, S., Duncan, L., and Djurdjev, O., et al. 1999.“Homocysteine and Vascular Access Complications in Haemodialysis Patients: Insights into a Complex Metabolic Relationship.” Nephrol. Dial. Transplant. 14: 738-43.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部